Related Experiment Videos
Progressive supranuclear palsy--20 years later
Acta Neurologica Scandinavica
|March 1, 1985
Summary
Progressive supranuclear palsy (PSP) remains a neurodegenerative disease with unknown etiology. Current understanding highlights key clinical features, diagnostic challenges, and neuropathological hallmarks, emphasizing the need for further research.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Progressive supranuclear palsy (PSP) has been recognized as a distinct clinicopathological entity for two decades.
- The etiology of PSP is currently unknown.
- PSP presents with characteristic supranuclear gaze palsy, axial rigidity, and pseudobulbar symptoms, often accompanied by cognitive and other neurological deficits.
Purpose of the Study:
- To delineate the current state of knowledge regarding progressive supranuclear palsy (PSP).
- To review the clinical, diagnostic, and neuropathological aspects of PSP.
- To outline the importance of ongoing research in PSP.
Main Methods:
- Literature review of studies published since the recognition of PSP as a clinicopathological entity.
- Analysis of clinical hallmarks, accessory features, and epidemiological data.
- Evaluation of current diagnostic tools and neuropathological findings.
Main Results:
- PSP typically affects individuals in their late 50s, with a male predominance.
- Early symptoms include dysequilibrium, mental changes, and visual disturbances, often preceding definitive neurological signs.
- Neuropathological findings include neurofibrillary tangles, neuron loss, and gliosis in specific brain regions.
Conclusions:
- Distinguishing PSP from parkinsonism is crucial due to poor treatment response and rapid progression in PSP.
- CT scanning and specialized neuro-examinations show promise as diagnostic tools.
- Further research into neurocytochemistry, brain ultrastructure, and immunology is vital for advancing PSP understanding and treatment.